Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telaglenastat + Everolimus in Advanced RCC
NCT03163667Phase 2Completed
- Sponsor
- Calithera Biosciences
- Start
- Sep 2017
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of telaglenastat in clear cell renal cell carcinoma (ccRCC), sponsored by Calithera Biosciences. Started Sep 2017; status: completed.
02
Drugs
telaglenastat
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT03163667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03163667.